<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Proteome Res</journal-id><journal-id journal-id-type="iso-abbrev">J Proteome Res</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of proteome research</journal-title></journal-title-group><issn pub-type="ppub">1535-3893</issn><issn pub-type="epub">1535-3907</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11636643</article-id><article-id pub-id-type="pmcid-ver">PMC11636643.1</article-id><article-id pub-id-type="pmcaid">11636643</article-id><article-id pub-id-type="pmcaiid">11636643</article-id><article-id pub-id-type="manuscript-id">NIHMS2037293</article-id><article-id pub-id-type="pmid">34014671</article-id><article-id pub-id-type="doi">10.1021/acs.jproteome.1c00022</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2037293</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2037293</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Metabolic Changes are Associated with Melphalan Resistance in Multiple Myeloma</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Koomen</surname><given-names initials="DC">David C.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meads</surname><given-names initials="MB">Mark B.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Magaletti</surname><given-names initials="DM">Dario M.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guingab-Cagmat</surname><given-names initials="JD">Joy D.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oliveira</surname><given-names initials="PS">Paula S.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="B">Bin</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="M">Min</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Welsh</surname><given-names initials="EA">Eric A.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meke</surname><given-names initials="LE">Laurel E.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="Z">Zhijie</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hampton</surname><given-names initials="OA">Oliver A.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tungesvik</surname><given-names initials="A">Alexandre</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>DeAvila</surname><given-names initials="G">Gabriel</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alugubelli</surname><given-names initials="RR">Raghunandan Reddy</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nishihori</surname><given-names initials="T">Taiga</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silva</surname><given-names initials="AS">Ariosto S.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eschrich</surname><given-names initials="SA">Steven A.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garrett</surname><given-names initials="TJ">Timothy J.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koomen</surname><given-names initials="JM">John M.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shain</surname><given-names initials="KH">Kenneth H.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1.</label>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612</aff><aff id="A2"><label>2.</label>University of Florida College of Medicine, Gainesville, FL 32610</aff><aff id="A3"><label>3.</label>M2Gen, Tampa, FL 33634</aff><author-notes><corresp id="CR1"><label>*</label>Co-corresponding Authors: Kenneth H. Shain, MD, PhD, Associate Member, Malignant Hematology, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, fax: (813) 745-7265, <email>ken.shain@moffitt.org</email>; John M. Koomen, PhD, Senior Member, Molecular Oncology, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, fax: (813) 745-3829, <email>john.koomen@moffitt.org</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P41">Conflict of Interest Statement</p><p id="P42">The following authors (OH and ZJ) are employed by M2Gen, a for profit company focused on providing oncology health informatics solutions to accelerate cancer treatment discovery, development, and delivery by leveraging clinical and molecular data.</p></fn></author-notes><pub-date pub-type="ppub"><day>04</day><month>6</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>20</day><month>5</month><year>2021</year></pub-date><volume>20</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">476885</issue-id><fpage>3134</fpage><lpage>3149</lpage><pub-history><event event-type="nihms-submitted"><date><day>24</day><month>11</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>12</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>12</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-17 16:25:16.470"><day>17</day><month>12</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2037293.pdf"/><abstract id="ABS1"><p id="P1">Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the U.S. Treatment for eligible patients involves induction, consolidation with stem cell rescue, and maintenance. High dose therapy with the DNA alkylating agent, melphalan, remains the primary drug for consolidation therapy in conjunction with autologous stem cell transplant; as such, melphalan resistance remains a relevant clinical challenge. Here, we describe a proteometabolomics approach to examine mechanisms of acquired melphalan resistance in two cell line models. Drug metabolism, steady-state metabolomics, activity-based protein profiling (ABPP, data available at PRIDE: PXD019725), acute treatment metabolomics, and western blot analyses have allowed us to further elucidate metabolic processes associated with melphalan resistance. Proteometabolomics data indicate that drug resistant cells have higher levels of pentose phosphate pathway metabolites. Purine, pyrimidine and glutathione metabolism were commonly altered, and cell line-specific changes in metabolite levels were observed, which could be linked to the differences in steady state metabolism of na&#239;ve cells. Inhibition of selected enzymes in purine synthesis and the pentose phosphate pathways was evaluated to determine their potential to improve melphalan&#8217;s efficacy. The clinical relevance of these proteometabolomics leads was confirmed by comparison of tumor cell transcriptomes from newly diagnosed MM patients and patients with relapsed disease after treatment with high dose melphalan and autologous stem cell transplantation. The observation of common and cell line specific changes in metabolite levels suggest that omics approaches will be needed to fully examine melphalan resistance in patient specimens and define personalized strategies to optimize the use of high dose melphalan.</p></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P2">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihms-2037293-f0007.jpg"/>
</p></abstract><kwd-group><kwd>Multiple Myeloma</kwd><kwd>Metabolism</kwd><kwd>Activity-based Protein Profiling (ABPP)</kwd><kwd>Proteometabolomics</kwd><kwd>Purines</kwd><kwd>Pentose Phosphate Pathway</kwd><kwd>LC-MS Metabolomics</kwd><kwd>RNAseq</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>